43 results about "Histone Acetyltransferases" patented technology

The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor, such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells to enhance their destruction by cytotoxic lymphocytes.

The invention discloses a construction method and an application of an electrochemical Faraday cage immunosensor for detecting the activity of histone acetyltransferase. The construction method comprises the following steps: (1) preparing peptide/Au: respectively taking acetyltransferase p300, polypeptide and acetyl-CoA, fully mixing the taken substances in PBS (0.1 M, pH 7.0), incubating the obtained solution in a constant-temperature water bath, taking and dropwise applying a catalytic reaction to the surface of a gold electrode, and incubating the gold electrode in a 4 DEG C refrigerator; (2) preparing MB&AuNPs@GO-Ab: mixing HAuCl4 and CTAB with water, adding ascorbic acid to the obtained reaction mixture, adding NaOH to obtain CTAB covered AuNPs, centrifuging and purifying the CTAB covered AuNPs, dispersing the purified CTAB covered AuNPs in an equal amount of water, adding GO to the obtained solution, performing ultrasonic dispersion, standing the dispersed solution for later use,adding an acetyl antibody, performing incubation, adding MB, and performing vibration and uniform mixing; and (3) producing the electrochemical Faraday cage immunosensor: taking and dropwise applyingthe MB&AuNPs@GO-Ab to the surface of the peptide/Au, performing incubation at room temperature, and placing the produced sensor in the PBS (0.1 M, pH 7.0) to carry out electrochemical SWV test.

The invention discloses a manufactured histone acetyltransferase electrochemiluminescence biosensor based on a DNA nano-prism and application of the histone acetyltransferase electrochemiluminescencebiosensor. The histone acetyltransferase electrochemiluminescence biosensor based on the DNA nano-prism is manufactured through the specific steps that (1) HAT-aptamer reaction is carried out, specifically, firstly, acetylation reaction is carried out, HATp300 and polypeptide are separately selected, and acetylcoenzyme A is fully mixed in a phosphate buffer solution (PBS, 10mM, pH7.0); secondly, CoA aptamer is added to the reaction solution in the first step; and thirdly, cDNA is added to the solution in the second step; and (2) the electrochemiluminescence sensor is manufacture through a. Auelectrode, b. prism/Au electrode, c. cDNA/prism/Au electrode, d. H1-H2/cDNA/prism/Au electrode and e. Ru/H1-H2/cDNA/prism/Au electrode. In the acetylation reaction, the concentration of p300 and the small molecule inhibitor concentration thereof are changed, and the effect of a series of sensors on an electrochemiluminescence signal is investigated. The manufactured histone acetyltransferase electrochemiluminescence biosensor based on the DNA nano-prism and the application of the histone acetyltransferase electrochemiluminescence biosensor have the advantages of good specificity, high sensitivity, fast detection speed, accurate and reliable results and low cost.

The invention discloses an electrochemical luminescence Faraday cage immunosensor for detecting histone acetyltransferase. The electrochemical luminescence Faraday cage immunosensor is characterized by comprising the following steps: (1) preparing a capturing unit: synthesizing magnetic graphene oxide (GO); treating the magnetic graphene oxide with an EDC/NHS (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride/N-Hydroxysuccinimide) solution and HCl in sequence; then combining with a capturing antibody Ab1; incubating at room temperature; finally adding BSA (Bovine Serum Albumin) to seal a non-specific binding site on the surface of the GO to obtain the capturing unit Ab1-nanoFe3O4@GO; (2) preparing a signal unit: connecting a recognition antibody Ab2 into a DNA (Deoxyribonucleic Acid) tetrahedron to synthesize tetrahedron-Ab2; then synthesizing nano-gold (AuNPs) and forming a compound GO@AuNPs by the nano-gold and graphene oxide; then combining the compound GO@AuNPs with tetrahedron-Ab2; then adding a Ru luminous body to prepare the signal unit; (3) preparing the Faraday cage immunosensor: dropping and coating an Ab1-nanoFe3O4@GO solution to the surface of an MGCE (Modified Glassy Carbon Electrode) to obtain Ab1-nanoFe3O4@GO/MGCE and recording as an electrode a; taking a p300 solution and dropping and coating on the Ab1-nanoFe3O4@GO/MGCE to obtain p300/Ab1-nanoFe3O4@GO/MGCE, and recording as an electrode b; finally, taking a Ru-GO@AuNPs-tetrahedron-Ab2 solution and dropping and coating on the p300/Ab1-nanoFe3O4@GO/MGCE to obtain a Ru-GO@AuNPs-tetrahedron-Ab2/p300/Ab1-nanoFe3O4@GO/MGCE, and recording as an electrode c, i.e., the electrochemical luminescence Faraday cage immunosensor.

The invention provides a heteroatom-containing novel high B-ring berberine analogue and a C-H activation synthesis method thereof. The novel high-B-ring berberine analogue with the potential p300 histone acetyltransferase inhibitory activity is prepared from 5-oxa-high B-ring berberine, 5-aza-high B-ring berberine and 5-thia-high B-ring berberine. According to the method, total synthesis is completed by virtue of desilicication and C-H activation/cyclization of cobalt-catalyzed N-picolinamide and arylacetylene silane. Compared with an existing report, the limitation of basic skeleton transformation of berberine is broken through, a novel structure type is provided, meanwhile, a more economical and efficient synthetic method of the berberine analogue is invented, and the berberine analoguehas a wide application prospect.

The present invention relates to a method for the diagnosis of low overall survival acute promyelocytic leukemia and/or of predicting and/or monitoring the response and/or the efficacy of a therapy for acute promyelocytic leukemia or to identify a subject to be treated with an inhibitor of HAT and/or an inhibitor of EZH2 by determining the acetylation or methylation status of specific relevant regions and relative kit and microarray. The invention also refers to histone acetyl transferase (HAT) inhibitor for use in the treatment of a solid or hematopoietic tumor.

Described herein is the use of bisamidoximes compounds for the treatment of cancer. In preferred embodiments, combinations of two or more bisamidoximes or combinations of a bisamidoxime and another anti-cancer agent were found to be effective against various types of cancer cells.

The invention provides an application of rictor/mTORC2 (mammalian target of rapamycin complex 2) in in-vitro differentiation of mouse embryonic stem cells into myocardial cells, namely a research applicable to screening and evaluation of a myocardial cell differentiation promoter taking rictor/mTORC2 as a target. According to the application, the myocardial cells from in-vitro directional differentiation of the mouse embryonic stem cells are purified by a percoll reagent, and plasmids of a histone acetyltransferase transcriptional coactivator p300 coded with rictor are transfected, so that a rictor acetylation level in the myocardial cells is raised, phosphorylation of a rictor downstream effector Akt (ser473) is further promoted, the activity of mTORC2 is improved, and a cardiomyocyte hypertrophy model is constructed; and furthermore, the cardiomyocyte hypertrophy model is utilized, an effect of resveratrol on resisting myocardial hypertrophy is evaluated, and the discovery of a novel myocardial differentiation inducer is facilitated.